Zhongnan Medical Journal Press

Home Results

A total of 4 result was found. Results that relate to HER2

CDK4/6 inhibitors in the first-line treatment of HR+/HER2- advanced stage breast cancer: a rapid health technology assessment

Published on Chinese Journal of Pharmacoepidemiology 2024,33(9):1017-1029.
14060 times 2344 times

LI Anna XIA Zhengzheng CAI Jiali LIAN Zhuoshi MENG Jun

CDK4/6 inhibitors Endocrine therapy HR+/HER2- advanced breast cancer Rapid health technology assessment
Details
Efficacy and safety of dose-optimization strategies for CDK4/6 inhibitors in HR+/HER2- advanced breast cancer: a Meta-analysis

Published on Chinese Journal of Pharmacoepidemiology 2025,34(7):795-805.
11776 times 1717 times

ZHENG Yating LIU Songling ZHOU Liyan

CDK4/6 inhibitor HR+/HER2- breast cancer Dose-optimization Meta-analysis
Details
Adverse event signal mining and analysis of tucatinib based on the FAERS database

Published on Frontiers in Pharmaceutical Sciences 2026,30(4):649-656.
2569 times 643 times

ZHAO Jun ZHAO Zhenying WANG Meisa LI Weiya JIANG Yuan YANG Fengkun

Tucatinib Breast cancer HER2 inhibitor FAERS database Adverse event Disproportionality method
Details
Meta-analysis of efficacy and safety of pertuzumab biosimilars versus original drug in the treatment of patients with HER2-positive breast cancer

Published on Chinese Journal of Pharmacoepidemiology 2026,35(7):810-817.
981 times 306 times

GU Shilong ZHANG Wenjing GUO Hao

Pertuzumab Biosimilars Original drug HER2 Breast cancer Efficacy Safety Meta-analysis
Details